

Jerome Sarris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2053987/publications.pdf>

Version: 2024-02-01

154
papers

9,768
citations

50170

46
h-index

43802

91
g-index

159
all docs

159
docs citations

159
times ranked

10732
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Psychedelic medicines for mood disorders: current evidence and clinical considerations. <i>Current Opinion in Psychiatry</i> , 2022, 35, 22-29. | 3.1 | 14 |
| 2 | Effects of <i>Bacopa monnieri</i> (CDRI 08 [®]) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial. <i>Phytotherapy Research</i> , 2022, 36, 996-1012. | 2.8 | 3 |
| 3 | N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550. | 2.5 | 5 |
| 4 | Disruptive innovation in psychiatry. <i>Annals of the New York Academy of Sciences</i> , 2022, 1512, 5-9. | 1.8 | 3 |
| 5 | Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455. | 1.3 | 49 |
| 6 | Assessing dietary, exercise, and non-pharmacological modalities within psychiatric hospitals. <i>General Hospital Psychiatry</i> , 2022, 76, 31-35. | 1.2 | 0 |
| 7 | Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310. | 0.9 | 2 |
| 8 | Lifestyle medicine for anxiety symptoms: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2022, 310, 354-368. | 2.0 | 13 |
| 9 | Quality control of cannabis inflorescence and oil products: Response factors for the cost-efficient determination of ten cannabinoids by HPLC. <i>Talanta Open</i> , 2022, 5, 100112. | 1.7 | 3 |
| 10 | Nutraceuticals and phytoceuticals for treating psychiatric disorders: a synopsis of the WFSBP and CANMAT 2022 clinician guidelines. <i>Jornal Brasileiro De Psiquiatria</i> , 2022, 71, 69-70. | 0.2 | 0 |
| 11 | A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273. | 0.9 | 11 |
| 12 | Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. <i>Nutritional Neuroscience</i> , 2021, 24, 279-295. | 1.5 | 14 |
| 13 | Potential mental and physical benefits of supplementation with a high-dose, B-complex multivitamin/mineral supplement: What is the evidence?. <i>Nutricion Hospitalaria</i> , 2021, 38, 1277-1286. | 0.2 | 2 |
| 14 | Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 849-862. | 0.9 | 19 |
| 15 | The Relationship between Oxidative Stress and Anxiety in a Healthy Older Population. <i>Experimental Aging Research</i> , 2021, 47, 322-346. | 0.6 | 4 |
| 16 | Yoga for depression and anxiety symptoms in people with cancer: A systematic review and meta-analysis. <i>Psycho-Oncology</i> , 2021, 30, 1196-1208. | 1.0 | 36 |
| 17 | Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1127-1133. | 1.3 | 24 |
| 18 | Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 623979. | 1.6 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. <i>Journal of Affective Disorders Reports</i> , 2021, 4, 100098. | 0.9 | 31 |
| 20 | Lifestyle medicine for depression: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2021, 284, 203-216. | 2.0 | 43 |
| 21 | Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression. <i>Frontiers in Nutrition</i> , 2021, 8, 669846. | 1.6 | 21 |
| 22 | Pyroluria: Fact or Fiction?. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 407-415. | 2.1 | 1 |
| 23 | The effect of vitamin C supplementation on mood status in adults: a systematic review and meta-analysis of randomized controlled clinical trials. <i>General Hospital Psychiatry</i> , 2021, 71, 36-42. | 1.2 | 8 |
| 24 | Pathophysiology of Major Depression by Clinical Stages. <i>Frontiers in Psychology</i> , 2021, 12, 641779. | 1.1 | 14 |
| 25 | Potential biomarkers of major depression diagnosis and chronicity. <i>PLoS ONE</i> , 2021, 16, e0257251. | 1.1 | 11 |
| 26 | Medicinal cannabis and driving: the intersection of health and road safety policy. <i>International Journal of Drug Policy</i> , 2021, 97, 103307. | 1.6 | 16 |
| 27 | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. <i>Psychopharmacology</i> , 2021, 238, 341-354. | 1.5 | 70 |
| 28 | Effects of a group-based lifestyle medicine for depression: A pilot randomized controlled trial. <i>PLoS ONE</i> , 2021, 16, e0258059. | 1.1 | 5 |
| 29 | Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. <i>PLoS ONE</i> , 2021, 16, e0258940. | 1.1 | 16 |
| 30 | Legalization of Psychedelic Substances. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2434. | 3.8 | 3 |
| 31 | Smartphone-delivered multicomponent lifestyle medicine intervention for depressive symptoms: A randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 970-984. | 1.6 | 12 |
| 32 | Improvement of cognitive function in schizophrenia with <i>N</i> -acetylcysteine: A theoretical review. <i>Nutritional Neuroscience</i> , 2020, 23, 139-148. | 1.5 | 29 |
| 33 | EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. <i>European Journal of Nutrition</i> , 2020, 59, 2439-2447. | 1.8 | 19 |
| 34 | S-Adenosylmethionine (S-AdoMet) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. <i>Psychopharmacology</i> , 2020, 237, 209-218. | 1.5 | 19 |
| 35 | Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive <i>N</i> -acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172. | 1.3 | 11 |
| 36 | Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 288-297. | 1.3 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Handgrip Strength Is Associated With Hippocampal Volume and White Matter Hyperintensities in Major Depression and Healthy Controls: A UK Biobank Study. <i>Psychosomatic Medicine</i> , 2020, 82, 39-46. | 1.3 | 44 |
| 38 | Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318. | 0.9 | 9 |
| 39 | Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. <i>Journal of Translational Medicine</i> , 2020, 18, 374. | 1.8 | 63 |
| 40 | Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N=84,860). <i>BMC Medicine</i> , 2020, 18, 354. | 2.3 | 60 |
| 41 | A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. <i>World Psychiatry</i> , 2020, 19, 360-380. | 4.8 | 424 |
| 42 | Herbal medicines and phytochemicals for obsessive-compulsive disorder. <i>Phytotherapy Research</i> , 2020, 34, 1889-1901. | 2.8 | 11 |
| 43 | Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. <i>Journal of Psychopharmacology</i> , 2020, 34, 1125-1133. | 2.0 | 60 |
| 44 | Zao Ren An Shen for insomnia: a systematic review with meta-analysis. <i>Sleep Medicine</i> , 2020, 69, 41-50. | 0.8 | 12 |
| 45 | Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. <i>BMC Psychiatry</i> , 2020, 20, 24. | 1.1 | 130 |
| 46 | A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 265, 233-238. | 2.0 | 12 |
| 47 | Omega-3 Fatty Acid Supplementation for Perinatal Depression and Other Subpopulations?. <i>Journal of Clinical Psychiatry</i> , 2020, 81, . | 1.1 | 4 |
| 48 | Is insomnia disorder associated with time in bed extension?. <i>Sleep Science</i> , 2020, 13, 215-219. | 0.4 | 0 |
| 49 | The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 675-712. | 3.7 | 815 |
| 50 | The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized-controlled trials. <i>World Psychiatry</i> , 2019, 18, 308-324. | 4.8 | 139 |
| 51 | International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 263-273. | 4.0 | 114 |
| 52 | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18. | 2.3 | 73 |
| 53 | Nutritional Psychiatry: From Concept to the Clinic. <i>Drugs</i> , 2019, 79, 929-934. | 4.9 | 30 |
| 54 | Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025640. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | What Is the Role of Dietary Inflammation in Severe Mental Illness? A Review of Observational and Experimental Findings. <i>Frontiers in Psychiatry</i> , 2019, 10, 350. | 1.3 | 64 |
| 56 | Harnessing the Four Elements for Mental Health. <i>Frontiers in Psychiatry</i> , 2019, 10, 256. | 1.3 | 13 |
| 57 | The "online brain": how the Internet may be changing our cognition. <i>World Psychiatry</i> , 2019, 18, 119-129. | 4.8 | 248 |
| 58 | The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. <i>Psychosomatic Medicine</i> , 2019, 81, 265-280. | 1.3 | 312 |
| 59 | Pilot-Testing of "Healthy Body Healthy Mind": An Integrative Lifestyle Program for Patients With a Mental Illness and Co-morbid Metabolic Syndrome. <i>Frontiers in Psychiatry</i> , 2019, 10, 91. | 1.3 | 13 |
| 60 | The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 115. | 1.3 | 16 |
| 61 | Alternative Treatments for Obsessive-Compulsive Disorder: Nutraceuticals and Lifestyle Interventions. , 2019, , 292-306. | | 0 |
| 62 | Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?. <i>Schizophrenia Research</i> , 2019, 210, 301-302. | 1.1 | 8 |
| 63 | L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2019, 110, 31-37. | 1.5 | 34 |
| 64 | Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. <i>Journal of Affective Disorders</i> , 2019, 245, 1007-1015. | 2.0 | 42 |
| 65 | Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 245-253. | 0.9 | 8 |
| 66 | The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depression. <i>Nutritional Neuroscience</i> , 2019, 22, 513-521. | 1.5 | 17 |
| 67 | Grip Strength Is Associated With Cognitive Performance in Schizophrenia and the General Population: A UK Biobank Study of 476559 Participants. <i>Schizophrenia Bulletin</i> , 2018, 44, 728-736. | 2.3 | 62 |
| 68 | Association Between Muscular Strength and Cognition in People With Major Depression or Bipolar Disorder and Healthy Controls. <i>JAMA Psychiatry</i> , 2018, 75, 740. | 6.0 | 54 |
| 69 | Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. <i>Phytotherapy Research</i> , 2018, 32, 1147-1162. | 2.8 | 120 |
| 70 | Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms. <i>Microbial Biotechnology</i> , 2018, 12, 774-783. | 0.9 | 17 |
| 71 | Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1275-1292. | 2.3 | 61 |
| 72 | Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial. <i>Nutritional Neuroscience</i> , 2018, 21, 224-228. | 1.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians. <i>Nutritional Neuroscience</i> , 2018, 21, 589-601. | 1.5 | 15 |
| 74 | The Validity and Value of Self-reported Physical Activity and Accelerometry in People With Schizophrenia: A Population-Scale Study of the UK Biobank. <i>Schizophrenia Bulletin</i> , 2018, 44, 1293-1300. | 2.3 | 77 |
| 75 | GABA-modulating phytochemicals for anxiety: A systematic review of preclinical and clinical evidence. <i>Phytotherapy Research</i> , 2018, 32, 3-18. | 2.8 | 78 |
| 76 | A Case of Acute Problem Gambling Associated With Agomelatine. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 153-155. | 0.7 | 4 |
| 77 | Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. <i>World Psychiatry</i> , 2018, 17, 365-367. | 4.8 | 102 |
| 78 | Adjunctive S-adenosylmethionine (SAME) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2018, 28, 1126-1136. | 0.3 | 29 |
| 79 | Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders. <i>Australasian Psychiatry</i> , 2017, 25, 369-372. | 0.4 | 20 |
| 80 | Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2017, 218, 15-22. | 2.0 | 552 |
| 81 | Herbal Anxiolytics with Sedative Actions. , 2017, , 11-31. | | 2 |
| 82 | Treatments for Comorbid Anxiety and Mood Disorders. , 2017, , 103-119. | | 0 |
| 83 | Potential Herbal Anxiolytics. , 2017, , 139-152. | | 0 |
| 84 | Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2017, 234, 403-420. | 1.5 | 21 |
| 85 | Polyunsaturated fatty acids and suicide risk in mood disorders: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 74, 43-56. | 2.5 | 30 |
| 86 | The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. <i>World Psychiatry</i> , 2017, 16, 287-298. | 4.8 | 755 |
| 87 | Ziziphus spinosa seeds for insomnia: A review of chemistry and psychopharmacology. <i>Phytotherapy Research</i> , 2017, 31, 38-43. | 2.3 | 58 |
| 88 | Exploring the Effect of Lactium® and Zizyphus Complex on Sleep Quality: A Double-Blind, Randomized Placebo-Controlled Trial. <i>Nutrients</i> , 2017, 9, 154. | 1.7 | 21 |
| 89 | A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression. <i>Depression Research and Treatment</i> , 2017, 2017, 1-10. | 0.7 | 40 |
| 90 | Videoconference mind-body group therapy in a public mental health setting: a pilot study. <i>Journal of Technology in Behavioral Science</i> , 2016, 1, 37-42. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Lifestyle Medicine for the Prevention and Treatment of Depression. , 2016, , 281-289. | | 0 |
| 92 | Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. American Journal of Psychiatry, 2016, 173, 575-587. | 4.0 | 315 |
| 93 | N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. BMC Psychiatry, 2016, 16, 320. | 1.1 | 34 |
| 94 | Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder. Clinical Psychological Science, 2016, 4, 1104-1111. | 2.4 | 8 |
| 95 | Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study. BMC Complementary and Alternative Medicine, 2016, 16, 60. | 3.7 | 27 |
| 96 | International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. World Psychiatry, 2015, 14, 370-371. | 4.8 | 81 |
| 97 | Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials, 2015, 16, 493. | 0.7 | 29 |
| 98 | Implementation of psychiatric-focused lifestyle medicine programs in Asia. Asia-Pacific Psychiatry, 2015, 7, 345-354. | 1.2 | 9 |
| 99 | N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. Clinical Psychopharmacology and Neuroscience, 2015, 13, 12-24. | 0.9 | 78 |
| 100 | A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI Tj ETQq0 0 0 rgBT /Overlock 10 T (ANZCTRN12612000827831). Nutrients, 2015, 7, 9931-9945. | 1.7 | 28 |
| 101 | Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira De Psiquiatria, 2015, 37, 03-12. | 0.9 | 38 |
| 102 | Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry,the, 2015, 2, 271-274. | 3.7 | 375 |
| 103 | An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Advances in Integrative Medicine, 2015, 2, 49-55. | 0.4 | 15 |
| 104 | Prevalence and predictors of herbal medicine use in adults experiencing anxiety: A critical review of the literature. Advances in Integrative Medicine, 2015, 2, 38-48. | 0.4 | 16 |
| 105 | N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. CNS Drugs, 2015, 29, 801-809. | 2.7 | 59 |
| 106 | Student attitudes towards clinical teaching resources in complementary medicine: a focus group examination of Australian naturopathic medicine students. Health Information and Libraries Journal, 2014, 31, 123-132. | 1.3 | 8 |
| 107 | Escitalopram Efficacy in Depression. Journal of Clinical Psychopharmacology, 2014, 34, 645-648. | 0.7 | 21 |
| 108 | S-adenosyl methionine (SAME) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders, 2014, 164, 76-81. | 2.0 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Effects of multivitamin, mineral and herbal supplement on cognition in younger adults and the contribution of B group vitamins. <i>Human Psychopharmacology</i> , 2014, 29, 73-82. | 0.7 | 15 |
| 110 | Lifestyle medicine for depression. <i>BMC Psychiatry</i> , 2014, 14, 107. | 1.1 | 265 |
| 111 | Naturopathic medicine for treating self-reported depression and anxiety: An observational pilot study of naturalistic practice. <i>Advances in Integrative Medicine</i> , 2014, 1, 87-92. | 0.4 | 6 |
| 112 | Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity – Fact or Fiction?. <i>Phytotherapy Research</i> , 2013, 27, 472-474. | 2.8 | 27 |
| 113 | Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 4. | 0.8 | 2 |
| 114 | Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects. <i>Phytotherapy Research</i> , 2013, 27, 1723-1728. | 2.8 | 81 |
| 115 | A randomized controlled trial investigating the effects of PCSO-524A®, a patented oil extract of the New Zealand green lipped mussel (<i>Perna canaliculus</i>), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066. <i>Nutrition Journal</i> , 2013, 12, 100. | 1.5 | 8 |
| 116 | St. John's Wort for the Treatment of Psychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2013, 36, 65-72. | 0.7 | 33 |
| 117 | Plant-Based Medicines for Anxiety Disorders, Part 1. <i>CNS Drugs</i> , 2013, 27, 207-219. | 2.7 | 53 |
| 118 | Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence. <i>CNS Drugs</i> , 2013, 27, 301-319. | 2.7 | 111 |
| 119 | Kava in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 643-648. | 0.7 | 99 |
| 120 | Mind-Body Medicine for Schizophrenia and Psychotic Disorders. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 7, 138-148. | 1.4 | 17 |
| 121 | Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. <i>Human Psychopharmacology</i> , 2013, 28, 516-522. | 0.7 | 36 |
| 122 | Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 827-830. | 0.7 | 3 |
| 123 | The Effects of Multivitamin Supplementation on Diurnal Cortisol Secretion and Perceived Stress. <i>Nutrients</i> , 2013, 5, 4429-4450. | 1.7 | 17 |
| 124 | St John's Wort (<i>Hypericum perforatum</i>) versus Sertraline and Placebo in Major Depressive Disorder: Continuation Data from a 26-Week RCT. <i>Pharmacopsychiatry</i> , 2012, 45, 275-278. | 1.7 | 27 |
| 125 | Integrative Mental Health (IMH): Paradigm, Research, and Clinical Practice. <i>Explore: the Journal of Science and Healing</i> , 2012, 8, 50-57. | 0.4 | 30 |
| 126 | Participant experiences from chronic administration of a multivitamin versus placebo on subjective health and wellbeing: a double-blind qualitative analysis of a randomised controlled trial. <i>Nutrition Journal</i> , 2012, 11, 110. | 1.5 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The Cognitive-Enhancing Effects of <i>Bacopa monnieri</i> : A Systematic Review of Randomized, Controlled Human Clinical Trials. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 647-652. | 2.1 | 100 |
| 128 | Chinese herbal medicine for sleep disorders: Poor methodology restricts any clear conclusion. <i>Sleep Medicine Reviews</i> , 2012, 16, 493-495. | 3.8 | 12 |
| 129 | Current challenges in appraising complementary medicine evidence. <i>Medical Journal of Australia</i> , 2012, 196, 310-311. | 0.8 | 23 |
| 130 | Genetic Technologies for Herbal Medicines in Psychiatry. <i>Phytotherapy Research</i> , 2012, 26, 522-527. | 2.8 | 17 |
| 131 | The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. <i>Human Psychopharmacology</i> , 2012, 27, 262-269. | 0.7 | 26 |
| 132 | Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 170-174. | 1.1 | 41 |
| 133 | Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review. <i>Journal of Affective Disorders</i> , 2012, 138, 213-221. | 2.0 | 46 |
| 134 | Omega-3 for Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 81-86. | 1.1 | 218 |
| 135 | Mental health and complementary and alternative medicine. , 2012, , 79-86. | | 0 |
| 136 | Re-introduction of Kava (<i>Piper methysticum</i>) to the EU: Is There a Way Forward?. <i>Planta Medica</i> , 2011, 77, 107-110. | 0.7 | 27 |
| 137 | Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2011, 106, 974-980. | 1.2 | 107 |
| 138 | Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 27-35. | 1.3 | 122 |
| 139 | Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A systematic review of the evidence. <i>Complementary Therapies in Medicine</i> , 2011, 19, 216-227. | 1.3 | 62 |
| 140 | A systematic review of insomnia and complementary medicine. <i>Sleep Medicine Reviews</i> , 2011, 15, 99-106. | 3.8 | 280 |
| 141 | Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 887-895. | 2.5 | 50 |
| 142 | Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. <i>European Neuropsychopharmacology</i> , 2011, 21, 841-860. | 0.3 | 372 |
| 143 | Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. <i>Bipolar Disorders</i> , 2011, 13, 454-465. | 1.1 | 69 |
| 144 | Kava, the anxiolytic herb: back to basics to prevent liver injury?. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 445-448. | 1.1 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Kava hepatotoxicity solution: A six-point plan for new kava standardization. <i>Phytomedicine</i> , 2011, 18, 96-103. | 2.3 | 42 |
| 146 | Bipolar Disorder and Complementary Medicine: Current Evidence, Safety Issues, and Clinical Considerations. <i>Journal of Alternative and Complementary Medicine</i> , 2011, 17, 881-890. | 2.1 | 21 |
| 147 | The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 446-454. | 2.2 | 144 |
| 148 | Clinical depression: an evidence-based integrative complementary medicine treatment model. <i>Alternative Therapies in Health and Medicine</i> , 2011, 17, 26-37. | 0.0 | 5 |
| 149 | Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. <i>Journal of Psychiatric Research</i> , 2010, 44, 32-41. | 1.5 | 69 |
| 150 | Comparative Use of Complementary Medicine, Allied Health, and Manual Therapies by Middle-Aged and Older Australian Women. <i>Journal of Women and Aging</i> , 2010, 22, 273-282. | 0.5 | 15 |
| 151 | St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. <i>Human Psychopharmacology</i> , 2009, 24, 41-48. | 0.7 | 24 |
| 152 | Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. <i>Nutrition Reviews</i> , 2009, 67, 125-131. | 2.6 | 64 |
| 153 | Kava and St. John's Wort: Current Evidence for Use in Mood and Anxiety Disorders. <i>Journal of Alternative and Complementary Medicine</i> , 2009, 15, 827-836. | 2.1 | 105 |
| 154 | Herbal medicines in the treatment of psychiatric disorders: a systematic review. <i>Phytotherapy Research</i> , 2007, 21, 703-716. | 2.8 | 123 |